(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator dokumenta: HR P20161115 T1

HR P20161115 T1

(12) PRIJEVOD PATENTNIH ZAHTJEVA EUROPSKOG PATENTA

(51) MKP:
C07D 213/64 (2006.01)
C07D 401/12 (2006.01)
C07D 405/12 (2006.01)
C07D 409/12 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
C07D 491/08 (2006.01)
C07D 491/107 (2006.01)
A61K 31/4412 (2006.01)
A61K 31/444 (2006.01)
A61P 35/00 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 18.11.2016.

(21) Broj predmeta: P20161115T

(22) Datum podnošenja zahtjeva u HR: 01.09.2016.

(86) Broj međunarodne prijave: PCT/US2012033648
Datum podnošenja međunarodne prijave: 13.04.2012.

(96) Broj europske prijave patenta: EP 12719529.5
Datum podnošenja europske prijave patenta: 13.04.2012.

(87) Broj međunarodne objave: WO 2012142504
Datum međunarodne objave: 18.10.2012.

(97) Broj objave europske prijave patenta: EP 2697199 A1
Datum objave europske prijave patenta: 19.02.2014.

(97) Broj objave europskog patenta: EP 2697199 B1
Datum objave europskog patenta: 08.06.2016.

(31) Broj prve prijave: 201161474821 P (32) Datum podnošenja prve prijave: 13.04.2011. (33) Država ili organizacija podnošenja prve prijave: US
201161499595 P 21.06.2011. US

(73) Nositelj patenta: **Epizyme, Inc., 400 Technology Square, 4th Floor, Cambridge, MA 02139, US**

(72) Izumitelji:
Kevin Wayne Kuntz, 8 New Village Road, Woburn, MA 01801, US
Richard Chesworth, 584 Strawberry Hill Road, Concord, MA 01742, US
Kenneth William Duncan, 132 Roosevelt Avenue, Norwood, MA 02062, US
Heike Keilhack, 3 Falmouth Street, Belmont, MA 02478, US
Natalie Warholic, 81 Strathmore Road, Apartment 32, Brighton, 02135 MA, US
Christine Klaus, 29 Weyham Road, Weymouth, MA 02191, US
Masashi Seki, Tsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukubashi, 300-2635 Ibaraki, JP
Syuji Shirotori, Tsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukubashi, 300-2635 Ibaraki, JP
Satoshi Kawano, Tsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukubashi, 300-2635 Ibaraki, JP
Timothy James Nelson Wigle, 111 Marivista Avenue, Waltham, MA 02451, US
Sarah Kathleen Knutson, 24 Bay State Road, Unit 22, Cambridge, MA 02138, US

(74) Zastupnik: PRODUCTA d.o.o., 10000 Zagreb, HR

(54) Naziv izuma: **ARIL- ILI HETEROARIL-SUPSTITUIRANI SPOJEVI BENZENA**

HR P20161115 T1

PATENTNI ZAHTJEVI

1. Spoj s formulom (I) ili njegova farmaceutski prihvatljiva sol:



(I),

naznačen time da

X_1 je N ili CR_{11};

X_2 je N ili CR_{13};

Z je NR_7R_8, OR_7, $S(O)_nR_7$, ili $CR_7R_8R_{14}$, gdje n je 0, 1, ili 2; svaki od R_1, R_5, R_9, i R_{10}, neovisno, je H ili C_1-C_6 alkil proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, hidroksil, COOH, C(O)O-C_1-C_6 alkil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, i 5- ili 6-člani heteroaril; svaki od R_2, R_3, i R_4, neovisno, je -Q_1-T_1, gdje Q_1 je veza ili C_1-C_3 alkil poveznica proizvoljno supstituirana s halo, cijano, hidroksil ili C_1-C_6 alkoksi, i T_1 je H, halo, hidroksil, COOH, cijano, ili RS_1, gdje R_{S1} je C_1-C_3 alkil, C_2-C_6 alkenil, C_2-C_6 alkinil, C_1-C_6 alkoksil, C(O)O-C_1-C_6 alkil, C_3-C_8 cikloalkil, C_6- C_{10} aril, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, 4 do 12-člani heterocikloalkil, ili 5- ili 6-člani heteroaril, i R_{S1} je proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, hidroksil,

okso, COOH, C(O)O-C_1-C_6 alkil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, i 5- ili 6-člani heteroaril;

R_6 je C_6-C_{10} aril ili 5- ili 6-člani heteroaril, svaki od kojih je proizvoljno supstituiran s jednim ili više -Q_2-T_2, pri čemu Q_2 je veza ili C_1-C_3 alkil poveznica proizvoljno supstituirana s halo, cijano, hidroksil ili C_1-C_6 alkoksi, i T_2 je H, halo, cijano, -OR_a, -NR_aR_b, -(NR_aR_bRC)+A-,-C(O)R_a, -C(O)OR_a, - C(O)NR_aR_b, -NR_bC(O)R_a, -NR_bC(O)OR_a, -$S(O)_2R_a$, -$S(O)_2NR_aR_b$, ili R_{s2}, gdje svaki od R_a, R_b, i RC, neovisno je H ili R_{S3}, A- je farmaceutski prihvatljiv anion, svaki od R_{S2} i R_{S3}, neovisno, je C_1-C_6 alkil, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, ili 5- ili 6-člani heteroaril, ili R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore 4 do 12-člani heterocikloalkilni prsten koji ima 0 ili 1 dodatni heteroatom, i svaki od R_{S2}, R_{S3}, te 4 do 12-člani heterocikloalkilni prsten koji tvore R_a i R_b, je proizvoljno supstituiran s jednim ili više -Q_3-T_3, pri čemu Q_3 je veza ili C_1-C_3 alkil poveznica svaki proizvoljno supstituiran s halo, cijano, hidroksil ili C_1-C_6 alkoksi, i T_3 se bira iz skupine koju čine halo, cijano, C_1-C_6 alkil, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, 5- ili 6-člani heteroaril, OR_d, $COOR_d$, -$S(O)_2R_d$, -NR_dR_e, i -C(O)NR_dR_e, svaki od R i R_e neovisno je H ili C_1-C_6 alkil, ili -Q_3-T_3 je okso; ili bilo koja dva susjedna -Q_2-T_2, zajedno s atomima na koje su oni vezani tvore 5- ili 6-člani prsten koji proizvoljno sadrži 1-4 heteroatoma koji se biraju od N, O i S i proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, hidroksil, COOH, C(O)O-C_1-C_6 alkil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, i 5- ili 6-člani heteroaril;

R_7 je -Q_4-T_4, gdje Q_4 je veza, C_1-C_4 alkil poveznica, ili C_2-C_4 alkenil poveznica, svaki poveznica proizvoljno supstituirana s halo, cijano, hidroksil ili C_1-C_6 alkoksi, i T_4 je H, halo, cijano, NR_fR_g, -OR_f, -C(O)R_f, -C(O)OR_f, -C(O)NR_fR_g, -C(O)NR_fOR_g, -$NR_fC(O)R_g$, -$S(O)_2R_f$, ili R_{s4}, gdje svaki od R_f i R_g, neovisno je H ili R_{S5}, svaki od R_{S4} i R_{S5}, neovisno je C_1-C_6 alkil, C_2-C_6 alkenil, C_2-C_6 alkinil, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, ili 5- ili 6-člani heteroaril, i svaki od R_{S4} i R_{S5} je proizvoljno supstituiran s jednim ili više -Q_5-T_5, pri čemu Q_5 je veza, C(O), C(O)NR_k, $NR_kC(O)$, $S(O)_2$, ili C_1-C_3 alkil poveznica, R_k je H ili C_1-C_6 alkil, i T_5 je H, halo, C_1-C_6 alkil, hidroksil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, 5- ili 6-člani heteroaril, ili $S(O)_qR_q$ gdje q je 0, 1, ili 2 i R_q je C_1-C_6 alkil, C_2-C_6 alkenil, C_2-C_6 alkinil, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, ili 5- ili 6-člani heteroaril, i T_5 je proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, C_1-C_6 alkil, hidroksil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-

C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, te 5- ili 6-člani heteroaril osim kada T_5 je H, halo, hidroksil, ili cijano; ili -Q_5-T_5 je okso;
svaki od R_8, R_{11}, R_{12}, i R_{13}, neovisno, je H, halo, hidroksil, COOH, cijano,
R_{S6}, OR_{S6}, ili $COOR_{S6}$, gdje R_{S6} je C_1-C_6 alkil, C_2-C_6 alkenil, C_2-C_6 alkinil, C_3-C_8 cikloalkil, 4 do 12-člani heterocikloalkil, amino, mono-C_1-C_6 alkilamino, ili di-C_1-C_6 alkilamino, i R_{S6} je proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, hidroksil, COOH, C(O)O-C_1-C_6 alkil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, i di-C_1-C_6 alkilamino; ili R_7 i R_8, zajedno s atomom N na koji su oni spojeni, tvore 4 do 11-člani heterocikloalkilni prsten koji ima 0 to 2 dodatnih heteroatoma, ili R_7 i R_8, zajedno s atomom C na koji su oni vezani, tvore C3- C8 cikloalkil ili 4 do 11-člani heterocikloalkilni prsten koji ima 1 do 3 heteroatoma, te svaki od 4 do 11-članih heterocikloalkilnih prstena ili C_3-C_8 cikloalkil koji tvore R_7 i R_8 je proizvoljno supstituiran s jednim ili više -Q6-T6, pri čemu Q6 je veza, C(O), $C(O)NR_m$, $NR_mC(O)$, $S(O)_2$, ili C_1-C_3 alkil poveznica, R_m je H ili C_1-C_6 alkil, i T6 je H, halo, C_1-C_6 alkil, hidroksil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, 5- ili 6-člani heteroaril, ili $S(O)_pR_p$ gdje p je 0, 1, ili 2 i R_p je C_1-C_6 alkil, C_2-C_6 alkenil, C2- C6 alkinil, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, ili 5- ili 6-člani heteroaril, i T6 je proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, C_1-C_6 alkil, hidroksil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino,
C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, i 5- ili 6-člani heteroaril osim kada T6 je H, halo, hidroksil, ili cijano; ili -Q6-T6 je okso; i R_{14} je odsutan, H, ili C_1-C_6 alkil proizvoljno supstituiran s jednim ili više supstituenata koji se biraju iz skupine koju čine halo, hidroksil, COOH, C(O)O-C_1-C_6 alkil, cijano, C_1-C_6 alkoksil, amino, mono-C_1-C_6 alkilamino, di- C_1-C_6 alkilamino, C_3-C_8 cikloalkil, C_6-C_{10} aril, 4 do 12-člani heterocikloalkil, i 5- ili 6-člani heteroaril.

2. Spoj prema zahtjevu 1, **naznačen time** da R_6 je fenil supstituiran s jednim ili više -Q_2- T_2; ili R_s je 5- ili 6-člani heteroaril koji sadrži 1-3 dodatnih heteroatoma koji se biraju od N, O, i S i proizvoljno supstituiran s jednim ili više -Q_2-T_2, poželjno 5- ili 6-člani heteroaril je piridinil, pirazolil, pirimidinil, kinolinil, tetrazolil, oksazolil, izoksazolil, tiazolil, izotiazolil, furil, ili tienil, svaki od kojih je proizvoljno supstituiran s jednim ili više -Q_2-T_2.
3. Spoj prema bilo kojem od zahtjeva 1-2, **naznačen time** da T2 je -NR_aR_b ili - $C(O)NR_aR_b$, gdje svaki od R_a i R_b, neovisno je H ili C_1-C_6 alkil, ili R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore 4 do 12-člani heterocikloalkilni prsten koji ima 0 ili 1 dodatni heteroatom, C_1-C_6 alkil i 4 do 12-člani heterocikloalkilni prsten koji je proizvoljno supstituiran s jednim ili više -Q3-T3, i Q2 je C_1-C_3 alkil poveznica proizvoljno supstituirana s halo ili hidroksilom.
4. Spoj prema bilo kojem od zahtjeva 1-3, **naznačen time** da R_7 je C_1-C_6 alkil, C_3-C_8 cikloalkil ili 4 do 12-člani heterocikloalkil, svaki proizvoljno supstituiran s jednim ili više -Q_5-T_5; ili R_7 je 4 do 12-člani heterocikloalkil proizvoljno supstituiran s jednim ili više -Q_5-T_5, poželjno R_7 je piperidinil, tetrahidropiran, tetrahidro-2H-tiopiranil,ciklopentil, ili cikloheksil, svaki proizvoljno supstituiran s jednim ili više -Q_5-T_5.
5. Spoj prema bilo kojem od zahtjeva 1-4, **naznačen time** da (i) jedan ili više -Q_5-T_5 su okso; ili (ii) T_5 je H, halo, C_1-C_6 alkil, C_1-C_6 alkoksil, C_3-C_8 cikloalkil, C_6-C_{10} aril, ili 4 do 12-člani heterocikloalkil; ili (iii) kada Q_5 je veza, T_5 je amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, C_1-C_6 alkil, C_3-C_8 cikloalkil, ili 4 do 12-člani heterocikloalkil; ili (iv) kada Q_5 je CO, $S(O)_2$, ili NHC(O), T_5 je C_1-C_6 alkil, C_1-C_6 alkoksil, C_3-C_8 cikloalkil, ili 4 do 12-člani heterocikloalkil; ili (v) kada Q_5 je C_1-C_3 alkil poveznica, T_5 je H, C_6-C_{10} aril, C_3-C_8 cikloalkil, 4 do 12-člani heterocikloalkil, ili $S(O)_qR_q$.
6. Spoj prema bilo kojem od zahtjeva 1-5, **naznačen time** da svaki od R_1 i R_{11} je H.
7. Spoj prema bilo kojem od zahtjeva 1-6, **naznačen time** da svaki od R_2 i R_4, neovisno je H ili C_1-C_6 alkil proizvoljno supstituiran s amino, mono-C_1-C_6 alkilamino, di-C_1-C_6 alkilamino, ili C_6-C_{10} aril, poželjno svaki od R_2 i R_4 je metil.
8. Spoj prema bilo kojem od zahtjeva 1-7, **naznačen time** da R_{12} je H, metil, etil, etenil, ili halo, $R_8$is H, metil, ili etil, i R_{13} je H ili metil.
9. Spoj prema zahtjevu 1, **naznačen time** da spoj ima Formulu (Ie):



(Ie),

poželjno spoj ima Formulu (Ig):



(Ig),

pri čemu R_2, R_4 i R_{12} su svaki, neovisno C_{1-6} alkil.

10. Spoj prema bilo kojem od zahtjeva 1 i 9, **naznačen time** da R_6 je C_6-C_{10} aril ili 5- ili 6- člani heteroaril, svaki od kojih je proizvoljno, neovisno supstituiran s jednim ili više - Q_2-T_2, pri čemu Q2 je veza ili C_1-C_3 alkil poveznica, i T2 je H, halo, cijano, -OR_a, - NR_aR_b, - (NR_aR_bRC)+A-, -$C(O)NR_aR_b$, -$NR_bC(O)R_a$, -$S(O)_2R$, ili R_{s2}, gdje svaki od R_a i R_b, neovisno je H ili RS3, svaki od R_{S2} i R_{S3}, neovisno, je C_1-C_6 alkil, ili R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore 4 do 7-člani heterocikloalkilni prsten koji ima 0 ili 1 dodatni heteroatom, i svaki od R_{S2}, R_{S3}, i 4 do 7-člani heterocikloalkilni prsten koji tvore R_a i R_b, je proizvoljno, neovisno supstituiran s jednim ili više -Q_3-T_3, pri čemu Q_3 je veza ili C_1-C_3 alkil poveznica i T_3 se bira iz skupine koju čine halo, C_1-C_6 alkil, 4 do 7-člani heterocikloalkil, OR_d, -$S(O)_2R_d$, i - NR_dR_e, svaki od R i R_e neovisno je H ili C_1-C_6 alkil, ili -Q_3-T_3 je okso; ili bilo koja dva susjedna -Q2-T2, zajedno s atomima na koje su oni vezani tvore 5- ili 6-člani prsten koji proizvoljno sadrži 1-4 heteroatoma koji se biraju od N, O i S.

11. Spoj prema bilo kojem od zahtjeva 1 i 9, **naznačen time** da spoj ima Formulu (II):



(II),

pri čemu Q_2 je veza ili metil poveznica,T_2 je H, halo, -OR_a, -NR_aR_b, -(NR_aR_bRC)+A- ili -$S(O)_2NR_aR_b$, R_7 je piperidinil, tetrahidropiran, ciklopentil, ili cikloheksil, svaki proizvoljno supstituiran s one -Q_5-T_5 i R_8 je etil, poželjno spoj ima Formulu (IIa):



(IIa).

12. Spoj prema bilo kojem od zahtjeva 1, 9, i 11, **naznačen time** da (i) svaki od R_a i R_b, neovisno je H ili C_1-C_6 alkil proizvoljno supstituiran s jednim ili više -Q_3-T_3, (ii) jedan od R_a i R_b je H, ili (iii) R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore 4 do 7-člani heterocikloalkilni prsten koji ima 0 ili 1 dodatnih heteroatoma na atomu N i prsten je proizvoljno supstituiran s jednim ili više -Q_3-T_3, poželjno R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore azetidinil, pirolidinil, imidazolidinil, pirazolidinil, oksazolidinil, izoksazolidinil, triazolidinil, tetrahidrofuranil, piperidinil, 1,2,3,6-tetrahidropiridinil, piperazinil, ili morfolinil, i prsten je proizvoljno supstituiran s jednim ili više -Q_3-T_3, i više poželjno R_a i R_b, zajedno s atomom N na koji su oni spojeni, tvore morfolinil.
13. Spoj prema zahtjevu 1, **naznačen time** da spoj je odabran od

Spoj broj	**Struktura**
1	
2	
3	
4	

5	
6	
7	
8	
9	
10	
11	

12	
13	
14	
15	
16	
17	
18	

19	
20	
21	
22	
23	
24	
25	

26	
27	
28	
29	
30	
31	
32	

35	
36	
37	
38	
39	

40	
41	
42	
43	
44	
45	

46	
47	
48	
49	
50	
51	

52	
53	
54	
55	
56	
57	

58	
59	
60	
61	
62	

63	
64	
65	
66	
67	

68	
69	
70	
71	
72	
73	

74	
75	
76	
77	
78	
79	

80	
81	
82	
83	
84	
85	

86	
87	
88	
89	
90	
91	

92	
93	
94	
95	
96	
97	

98	
99	
100	
101	
102	
103	

104	
105	
106	
107	
108	

109	
110	
111	
112	
113	

114	
115	
116	
117	
118	

119	
120	
121	
122	
123	

124	
125	
126	
127	
128	

129	
130	
131	
132	
133	

134	
135	
136	
137	
138	

139	
140	
141	
142	
143	

144	
145	
146	
147	
148	
149	

150	
151	
152	
153	
154	
155	

156	
158	
159	
160	
161	
162	

163	
164	
165	
166	
167	
168	

169	
170	
171	
172	
173	

174	
175	
176	
177	
178	

179	
180	
181	
182	
183	

184	
185	
186	
187	

188	
189	
190	
191	

192	
193	
194	
195	

196	
197	
198	
199	

200	

i njihove farmaceutski prihvatljive soli, te je poželjno spoj odabran od

Spoj broj	**Struktura**
1	
2	
11	
12	
13	

17	
20	
21	
36	
42	
43	

44	
59	
65	
67	
68	

69	
73	
75	
76	
78	
80	

82	
83	
87	
88	
89	
90	

91	
94	
97	
103	
105	
138	

141	

i njihove farmaceutski prihvatljive soli.

14. Spoj prema zahtjevu 1, **naznačen time** da spoj je



ili njegova farmaceutski prihvatljiva sol.

15. Farmaceutski pripravak **naznačen time** da sadrži spoj prema bilo kojem od zahtjeva 114 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
16. Spoj prema bilo kojem od zahtjeva 1-14 **naznačen time** da je za upotrebu u postupku liječenja ili sprječavanja raka.